|Day's Range||32.10 - 32.29|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.40|
|Dividend & Yield||1.28 (3.98%)|
|1y Target Est||N/A|
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be presented ...
Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.
Total prescriptions of Pfizer's eczema drug Eucrisa have flattened out over recent weeks as Regeneron and Sanofi's Dupixent has picked up steam.